Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide maintenance was similar to that with indefinite-duration maintenance. The full phase 3 ENDURANCE trial results are summarized in a new Quick Take video: https://nej.md/4wKhrar

3 likes 0 replies